[Ventriculography with non-ionic water-soluble contrast medium, Amipaque (metrizamide)-experimental and clinical study (author's transl)].
The excellently low toxicity of a non-ionic watersoluble contrast medium Amipaque (Metrizamide), which is used for ventriculography, was confirmed by animal experiment and clinical application. In the animal experiment, 20 adult mongrel dogs were used and in each of them 1.5-5.0 ml of Amipaque was injected intraventriculary or intracisternally. As a result, we obtained a finding that the Amipaque is cleary safe compared with other watersoluble contrast media, espcially on epileptogenicity, while having an effect on the definition of picture and the nature of cerebrospinal fluid similar to other watersoluble contrast media. Thereafter, 14 ventriculographies were performed for 11 neurosurgical patients by using 4-10 ml of amipaque. Though one patient complained of a light headache after the examination, in no cases could convulsive complication be observed. The experience of this new medium gave us an impression that ventriculography with watersoluble contrast media will take the place of pneumoventriculography.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D001932:Brain Neoplasms / Q000000981:diagnostic imaging; D014695:Cerebral Ventriculography; D002648:Child; D003287:Contrast Media; D004285:Dogs; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D008297:Male; D008793:Metrizamide; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D010148:Intractable Pain / Q000000981:diagnostic imaging / Q000601:surgery; D010871:Pinealoma / Q000000981:diagnostic imaging
D003287:Contrast Media; D007463:Iodobenzoates; D008793:Metrizamide